RefleXion is a developer of a biology-guided radiotherapy system that aims to create a significant change in strategy from single tumor therapy to the ability to treat multiple tumors in the same treatment session in cancers that have metastasized. The company’s SCINTIX® technology has a mission of tracking period tumor and non-tumor motion to reach its goal of creating a dual treatment modality. RefleXion was founded by Akshay Nanduri and Sam Mazin in 2009 and is headquartered in Hayward, CA.
Access RefleXion Medical’s valuation and stock price.
View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies.
Become part of the Secondary Marketplace, catering to both individual and institutional investors.
The Rise Fund, Pictet, Square Point Capital, Ally Bridge, Pfizer Ventures, Johnson & Johnson Innovation, T.Rowe Price Associates, Venrock, Catalio, Hillenbrand
Price per Share
$xx.xx
Shares Outstanding
21,839,817
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
800.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
1000
Key Investors
The Rise Fund, Pictet, Square Point Capital, Ally Bridge, Pfizer Ventures, Johnson & Johnson Innovation, T.Rowe Price Associates, Venrock, Catalio, Hillenbrand
11/15/2023
Series E-X
$18.01MM
$xx.xx
$1.34B
The Rise Fund, Pictet, Square Point Capital, Ally Bridge, Pfizer Ventures, Johnson & Johnson Innovation, T.Rowe Price Associates, Venrock, Catalio, Hillenbrand
Price per Share
$xx.xx
Shares Outstanding
7,597,170
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.4x
Dividend Rate
800.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
The Rise Fund, Pictet, Square Point Capital, Ally Bridge, Pfizer Ventures, Johnson & Johnson Innovation, T.Rowe Price Associates, Venrock, Catalio, Hillenbrand
11/15/2023
Series D-X
$20.47MM
$xx.xx
$1.34B
The Rise Fund, Pictet, Square Point Capital, Ally Bridge, Pfizer Ventures, Johnson & Johnson Innovation, T.Rowe Price Associates, Venrock, Catalio, Hillenbrand
Price per Share
$xx.xx
Shares Outstanding
10,734,817
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.3x
Dividend Rate
800.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
The Rise Fund, Pictet, Square Point Capital, Ally Bridge, Pfizer Ventures, Johnson & Johnson Innovation, T.Rowe Price Associates, Venrock, Catalio, Hillenbrand
11/15/2023
Series D-1-X
$6.55MM
$xx.xx
$1.34B
The Rise Fund, Pictet, Square Point Capital, Ally Bridge, Pfizer Ventures, Johnson & Johnson Innovation, T.Rowe Price Associates, Venrock, Catalio, Hillenbrand
Price per Share
$xx.xx
Shares Outstanding
2,872,489
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.4x
Dividend Rate
800.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
The Rise Fund, Pictet, Square Point Capital, Ally Bridge, Pfizer Ventures, Johnson & Johnson Innovation, T.Rowe Price Associates, Venrock, Catalio, Hillenbrand
11/15/2023
Series C-X
$16.8MM
$xx.xx
$1.34B
The Rise Fund, Pictet, Square Point Capital, Ally Bridge, Pfizer Ventures, Johnson & Johnson Innovation, T.Rowe Price Associates, Venrock, Catalio, Hillenbrand
Price per Share
$xx.xx
Shares Outstanding
9,928,010
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.3x
Dividend Rate
800.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
The Rise Fund, Pictet, Square Point Capital, Ally Bridge, Pfizer Ventures, Johnson & Johnson Innovation, T.Rowe Price Associates, Venrock, Catalio, Hillenbrand
11/15/2023
Series B-X
$8.51MM
$xx.xx
$1.34B
The Rise Fund, Pictet, Square Point Capital, Ally Bridge, Pfizer Ventures, Johnson & Johnson Innovation, T.Rowe Price Associates, Venrock, Catalio, Hillenbrand
Price per Share
$xx.xx
Shares Outstanding
7,891,388
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
800.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
The Rise Fund, Pictet, Square Point Capital, Ally Bridge, Pfizer Ventures, Johnson & Johnson Innovation, T.Rowe Price Associates, Venrock, Catalio, Hillenbrand
11/15/2023
Series A-X
$1.92MM
$xx.xx
$1.34B
The Rise Fund, Pictet, Square Point Capital, Ally Bridge, Pfizer Ventures, Johnson & Johnson Innovation, T.Rowe Price Associates, Venrock, Catalio, Hillenbrand
Price per Share
$xx.xx
Shares Outstanding
5,583,233
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
800.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
The Rise Fund, Pictet, Square Point Capital, Ally Bridge, Pfizer Ventures, Johnson & Johnson Innovation, T.Rowe Price Associates, Venrock, Catalio, Hillenbrand
03/10/2022
Series E
$110MM
$xx.xx
$785.79MM
Ascension Ventures, Catalio Capital Management, Sixty Degree Capital, Hillenbrand Capital Partners, The Rise Fund, KCK Group, PSP Investments, T. Rowe Price, Ally Bridge Group, Venrock, Pfizer Ventures Investments, Johnson & Johnson Innovation
Price per Share
$xx.xx
Shares Outstanding
46,402,813
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.4x
Dividend Rate
800.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Ascension Ventures, Catalio Capital Management, Sixty Degree Capital, Hillenbrand Capital Partners, The Rise Fund, KCK Group, PSP Investments, T. Rowe Price, Ally Bridge Group, Venrock, Pfizer Ventures Investments, Johnson & Johnson Innovation
03/02/2021
Series D-1
$40MM
$xx.xx
$650.69MM
Ally Bridge Group
Price per Share
$xx.xx
Shares Outstanding
17,544,898
Liquidation Pref Order
4
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.4x
Dividend Rate
800.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Ally Bridge Group
04/16/2020
Series D
$125MM
$xx.xx
$496.89MM
The Rise Fund, T. Rowe Price Associates, GT Healthcare Capital Partners, Sofinnova Partners, KCK Group, Venrock, Pfizer Venture Investments, Johnson & Johnson Innovation
Price per Share
$xx.xx
Shares Outstanding
65,567,269
Liquidation Pref Order
4
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.3x
Dividend Rate
800.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
The Rise Fund, T. Rowe Price Associates, GT Healthcare Capital Partners, Sofinnova Partners, KCK Group, Venrock, Pfizer Venture Investments, Johnson & Johnson Innovation
04/04/2018
Series C
$102.6MM
$xx.xx
$322.47MM
The Rise Fund, T. Rowe Price Associates, GT Healthcare Capital Partners, Sofinnova Partners, KCK Group, Venrock, Pfizer Venture Investments, Johnson & Johnson Innovation
Price per Share
$xx.xx
Shares Outstanding
60,639,366
Liquidation Pref Order
5
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.3x
Dividend Rate
800.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
The Rise Fund, T. Rowe Price Associates, GT Healthcare Capital Partners, Sofinnova Partners, KCK Group, Venrock, Pfizer Venture Investments, Johnson & Johnson Innovation
07/19/2016
Series B
$52MM
$xx.xx
$118.39MM
KCK Group, Venrock, Pfizer Venture Investments, Sofinnova Partners, Johnson & Johnson Innovation
Price per Share
$xx.xx
Shares Outstanding
48,199,870
Liquidation Pref Order
6
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
800.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
KCK Group, Venrock, Pfizer Venture Investments, Sofinnova Partners, Johnson & Johnson Innovation
As RefleXion Medical is not publicly traded, purchasing its stock is not available to everyone. To buy the stock of a private companies like RefleXion Medical, you must be an accredited investor. If you meet the accreditation criteria, you can register for Forge’s Secondary Marketplace to buy private market stock. If you are not accredited, find out how to begin the process and qualify for new investment opportunities.
How to buy RefleXion Medical stock?
To invest in a private company like RefleXion Medical through Forge, you must first qualify as an accredited investor. (Learn more about the accreditation process.)
Create a free account to access Forge’s marketplace.
Express your interest in specific investments. Within Forge Markets, you will find detailed pricing and financing information for thousands of private companies.
Throughout this process, a dedicated Forge Private Market Specialist will be available to address any questions you may have and to guide you seamlessly through each step of the transaction.
Can you sell RefleXion Medical stock?
Yes, you may sell the RefleXion Medical stock you currently own. Forge can help you facilitate the sale of your stock in a manner that aligns with your needs and the company’s interests. If you are looking for liquidity, register with us today to begin the process. A dedicated Forge Private Market Specialist will be available to address any questions you may have along the way.
How to sell RefleXion Medical stock?
If you hold private company shares of RefleXion Medical – whether as an employee or an early investor – Forge can help you sell them.
Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have.
Indicate your interest to sell your RefleXion Medical on our platform.
Work with your dedicated Private Market Specialist who’ll help guide you through every step of the transaction.
Is RefleXion Medical a public company?
No, RefleXion Medical is a privately held company and is currently not publicly traded on any stock markets including NYSE or NASDAQ.
What is RefleXion Medical’s stock price?
RefleXion Medical is a privately held company and therefore does not have a public stock price. However, you may access RefleXion Medical private market stock price with Forge Data.
What is RefleXion Medical’s stock ticker symbol?
RefleXion Medical does not have an official ticker symbol because this company is not currently publicly traded.
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.
Other companies like RefleXion Medical in the Medical Devices sector
RefleXion® Medical, a therapeutic oncology company, today announced the company will showcase the RefleXion® X1 with SCINTIX™ biology-guided radiotherapy at the American Society for Radiation Oncology (ASTRO) Annual Meeting, Oct. 1-4, 2023 in San Diego (booth #2831). Researchers from multiple clinical programs will present new scientific evidence in 20 presentations, including two oral presentations, supporting the potential of SCINTIX therapy, which is delivered only through the X1 platform.
RefleXion Medical has acquired the exclusive rights to develop and commercialize a specific molecule, RXM-4768, from 3B Pharmaceuticals. This molecule targets fibroblast activation proteins found in nearly all solid tumor types and could expand the patient population eligible for Scintix therapy. The deal includes upfront and annual license payments to 3B Pharmaceuticals, with additional payments upon certain milestones.
RefleXion Medical has announced the first patient has completed treatment using its Scintix biology-guided radiotherapy on its X1 machine. The treatment uses the individual biology of each tumor to determine the amount of radiation required, receiving FDA clearance in February of this year. The company expects to offer the treatment in specific cancer centers in California, Pennsylvania, and Texas soon, with New Jersey, Connecticut, and Oregon to follow by the end of 2023.
RefleXion Medical has developed an innovative biology-guided radiotherapy, Scintix, which uses cancer's unique biology for controlled radiotherapy delivery. The treatment received FDA clearance in February 2023 and is indicated for lung and bone cancers. The Scintix technology can detect and treat various moving cancers without affecting healthy tissues. This development represents a significant advancement in the field of oncology.
PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES
1. Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge. Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.
2. The Last Closed Trade price displayed reflects the price at which the last trade in this company's security occurred on Forge, and can include secondary trades in any class of the company's security, or trades in units of funds holding the company's securities (the economics of which differ versus direct company ownership). The date displayed reflects the date on which the last trade in this company's security closed on Forge. This may be several weeks after the terms of the trade were agreed upon between the buyer and seller. In case of multiple trades closed on the same date, the price displayed is of either (i) the trade which terms were agreed upon most recently; or (ii) the trade with the higher notional value.
‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.
Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.
Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.
November Private Market Update
